Esperer Bioresearch strengthens its senior leadership team

IMT News Desk
IMT News Desk
· 2 min read

New Delhi , 9th September, 2019: Esperer Bioresearch Pvt. Ltd, one of India’s first nutritional companies for cancer patients today inducts industry veteran Dhruv Ashish Arora as their Global Business Head. Having more than 17 years of experience in Healthcare, Banking and Market Research industry, Dhruv Arora has worked across geographies on a variety of transactions such business model restructuring, stake holder networking, relationship management and market analysis with good business foresight and regulatory understanding.

In his role at Esperer Bioresearch, Dhruv Arora will be responsible for strategizing and overseeing all export related activities for the companies Pharmaceutical & First time in the World to be a Patented Cancer-Nutrition Product formulation Technology. He will be based out of Mumbai and will report to the Founder & CEO, Raktim Chattopadhyay.

Dhruv’s previous stint comprises of M/S Vins Bio Products Pvt. Ltd. Hyderabad, Bharat Serums & Vaccines Ltd, Mumbai and M/S Goldshield PLC. His competencies include identifying new markets operations for its Business Development activities. In his last assignment, at Vino Bins Products Ltd. he was the Vice President- Exports and was responsible for re-structuring marketing, regulatory & logistics and brought a strategic growth in sales for the company. He also gave outstanding performance for 7 Years as Country Manager Russia, Deputy General Manager Mena (Middle East & North Africa) & South East Asia, ROW (Rest of the World) Business Head.

“We are extremely pleased to welcome Dhruv as our Global Business Head. I am certain that his diverse, comprehensive experience will provide significant confidence and provide tremendous benefit to our business. Dhruv’s appointment is imperative to our approach in discovering new growth avenues and providing a new dimension of our presence in the industry.” added Raktim Chattopadhyay, Founder & CEO Esperer Bioresearch.

Speaking on his appointment, Dhruv Arora said “It is a pleasure to be part of Esperer Bioresearch, offering me a compelling platform to build and nurture the business in this rapidly changing environment. I am looking forward to creating zestful working in organization, scaling the business to new heights.”

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk